Stuart Poulton
Fortune : 926 401 $ au 30/06/2026
Fortune : 926 401 $ au 30/06/2026
Stuart Poulton is Chief Development Officer & Executive VP at Karyopharm Therapeutics, Inc. since 2022.
Formerly, Mr. Poulton was Vice President-Clinical Development Operations at AbbVie, Inc. from 2019 to 2022, Executive Director-Global Program Management at Amgen, Inc. from 2013 to 2016, and Head-Clinical Operations at Eli Lilly & Co. Education includes graduate studies at The University of New South Wales and undergraduate studies at The University of Sydney.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/05/2026 | 94 821 ( 0,42 % ) | 926 401 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | 01/02/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/01/2022 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2016 |
| ELI LILLY AND COMPANY | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
The University of New South Wales
The University of New South Wales Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Sydney
The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national